Antihyperlipidemic effect of curcumin and tetrahydrocurcumin in experimental type 2 diabetic rats

Renal Failure

Volumn 29, Issue 7, 2007, Pages 881-889

  Pari, Leelavinothan ^a   Murugan, Pidaran ^a  

^a ANNAMALAI UNIVERSITY   (India)

Author keywords

Blood glucose; HMG CoA reductase; Plasma insulin; Total lipids; Type 2 diabetes

Indexed keywords

ANTIDIABETIC AGENT; ANTILIPEMIC AGENT; CHOLESTEROL; CURCUMIN; FATTY ACID; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; INSULIN; LIPID; LOW DENSITY LIPOPROTEIN; NICOTINAMIDE; PHOSPHOLIPID; STREPTOZOCIN; TETRAHYDROCURCUMIN; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; VERY LOW DENSITY LIPOPROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHEMICAL ANALYSIS; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL LIVER LEVEL; CONTROLLED STUDY; DISEASE CONTROL; DRUG EFFECT; ENZYME ACTIVITY; EXPERIMENTAL DIABETES MELLITUS; FATTY ACID BLOOD LEVEL; GLUCOSE BLOOD LEVEL; HISTOPATHOLOGY; INSULIN BLOOD LEVEL; LIPOPROTEIN BLOOD LEVEL; MALE; METABOLITE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PHOSPHOLIPID BLOOD LEVEL; PRIORITY JOURNAL; RAT; STATISTICAL SIGNIFICANCE; STREPTOZOCIN DIABETES; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL;

ANIMALS; ANTILIPEMIC AGENTS; BLOOD GLUCOSE; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CURCUMIN; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 2; HYDROXYMETHYLGLUTARYL COA REDUCTASES; LIPID METABOLISM; LIVER; MALE; RATS; RATS, WISTAR; STREPTOZOCIN;

EID: 36248994780     PISSN: 0886022X     EISSN: 15256049     Source Type: Journal    
DOI: 10.1080/08860220701540326     Document Type: Article

References (48)

1. Howard BV, Savage PJ, Bennion LJ, Bennett PH. Lipoprotein composition in diabetes mellitus. Atheroscler. 1978;30:153-162.
2. Nikkila EA, Kekki M. Plasma triglyceride transport in diabetes mellitus. Metabolism. 1973;22:1-22.
3. Satyanarayana K. Chemical examination of Scoparia dulcis (Linn): Part I. J. Indian Chem. Soc. 1969;46:765-766.
4. Sochor M, Baquer NZ, McLean P. Glucose over and under utilization in diabetes: Comparative studies on the changes in the activities of enzymes of glucose metabolism in rat kidney and liver. Mol. Physiol. 1985;7:51-68.
5. Gupta BL, Baquer NZ. Hexokinase, glucose-6-phosphate dehydrogenase and antioxidant enzymes in diabetic reticulocytes: Effects of insulin and vanadate. Biochem. Mol. Biol. Int. 1998;46:1145-1152.
6. Aggarwal B, Kumar A, Bharti A. Anticancer potential of curcumin: Preclinical and clinical studies. Anticancer Res. 2003;23:363-398.
7. Babu P, Srinivasan K. Hypolipidemic action of curcumin, the active principle of turmeric Curcuma longa in streptozotocin induced diabetic rats. Mol. Cell. Biochem. 1997;166:169-175.
8. Suryanarayana P, Saraswat M, Mrudula T, Krishna P, Krishnaswamy K, Reddy G. Curcumin and turmeric delay streptozotocin-induced diabetic cataract in rats. Invest. Ophthalmol. Vis. Sci. 2005;46:2092-2099.
9. Babu P, Srinivasan K. Amelioration of renal lesions associated with diabetes by dietary curcumin in streptozotocin diabetic rats. Mol. Cell. Biochem. 1998;181:87-96.
10. Sajithlal G, Chithra P, Chandrakasan G. Effect of curcumin on the advanced glycation and cross-linking of collagen in diabetic rats. Biochem. Pharmacol. 1998;56:1607-1614.
11. Nishiyama T, Mae T, Kishida H, Tsukagawa M, Mimaki Y, Kuroda M. Curcuminoids and sesquiterpenoids in turmeric (Curcuma longa L) suppress and increase in blood glucose level in type 2 diabetic KK-Ay mice. J. Agric. Food. Chem. 2005;53:959-963.
12. Mahesh T, Balasubashini M, Menon V. Effect of photo-irradiated curcumin treatment against oxidative stress in streptozotocin-induced diabetic rats. J. Med. Food. 2005;8:251-255.
13. Sidhu G, Mani H, Gaddipati J, Singh A, Seth P, Banaudha K. Curcumin enhances wound healing in streptozotocin induced diabetic rats and genetically diabetic mice. Wound. Rep. Regen. 1999;7:362-374.
14. Holder GM, Plummer JL, Ryan AJ. The metabolism and excretion of curcumin (1,7,-bis(4-hydroxy-3-methoxyphenyl)-1,6-hepadiene-3,5-dione) in rat. Xenobiotica. 1978;8:761-768.
15. Naito M, Wu X, Normura H, Kodama M, Kato Y, Osaswa T. The protective effect of tetrahydrocurcumin on oxidative stress in cholesterol-fed rabbits. J. Atheroscler. Thromb. 2002;9:243-250.
16. Okada K, Wangpoengtrakul C, Tanaka T, Toyokuni S, Uchida K, Osawa T. Curcumin and especially tetrahydrocurcumin ameliorate oxidative stress-induced renal injury in mice. J. Nutr. 2001;31:2090-2095.
17. Pari L, Murugan P. Protective role of tetrahydrocurcumin against erythromycin estolate induced hepatotoxicity. Pharmacol. Res. 2004;49:481-486.
18. Sugiyama Y, Kawakishi S, Osawa T. Involvement of the β-diketone moiety in the antioxidant mechanism of tetrahydrocurcuminoids. Biochem. Pharmacol. 1996;52:519-525.
19. Lin JK, Lin-Shiau SY. Mechanisms of cancer chemoprevention by curcumin. Pro. Natl. Sci. Counc. Repub. China. 2001;25:59-66.
20. Pari L, Murugan P. Effect of tetrahydrocurcumin on blood glucose, plasma insulin and hepatic key enzymes in streptozotocin induced diabetic rats. J. Basic Clin. Physiol. Pharmacol. 2005;16:257-274.
21. Masiello P, Broca C, Gross R, Roye M, Manteghetti M, Hillaire-Buys D. Experimental NIDDM: Development of a new model in adult rats administered streptozotocin and nicotinamide. Diabetes. 1998;47:224-229.
22. Murugan P, Pari L. Antioxidant effect of tetrahydrocurcumin in streptozotocin - nicotinamide induced diabetic rats. Life Sci. 2006;79:1720-1728.
23. Folch J, Lees M, Solane SGH. A simple method for isolation and purification of total lipids from animal tissues. J. Biol. Chem. 1957;226:497-509.
24. Lott JA, Turner K. Evaluation of trinder's glucose oxidase method for measuring glucose in serum and urine. Clin. Chem. 1975;21/12:1754-1760.
25. Zlatkis A, Zak B, Boyle GJ. A method for the determination of serum cholesterol. J. Clin. Med.1953;41:486-492.
26. Burnstein M, Scholnic MR, Mortin R. Rapid method of isolation of lipoprotein from human serum by precipitation of polyanion. J. Lipid Res. 1970;11:583-587.
27. Friedwerd WT, Levy RI, Fredrickson DS. Estimation of concentration of low-density lipoprotein cholesterol in plasma, without the use of the preparative ultracentrifuge. Clin. Chem. 1972;18:499-502.
28. Foster JB, Dunn RT. Stable reagents for determination of serum triglyceride by colorimetric condensation method. Clin. Chim. Acta. 1973;19:338-340.
29. Falholt K, Falholt W, Lund B. An assay colorimetric method for routine determination of free fatty acids in plasma. Clin. Chim. Acta.1973;46: 105-111.
30. Zilversmit BB, Davis AK. Micro determination of plasma phospholipids by TCA precipitation. J. Lab. Clin. Med. 1950;35:155-160.
31. Philipp B, Shapiro DJ. Improved methods for the assay and activation of 3-hydroxy-3-methylglutaryl-co-enzyme A reductase. J. Food Res. 1979;20:588-593.
32. Duncan BD. Multiple range test for correlated and heteroscedastic means. Biometrics. 1957;13:359-364.
33. Scheen AJ. Pathophysiology of type 2 diabetes. Acta. Clin. Belg. 2003;58:335-341.
34. Maassen JA, Van den Ouweland JM, Losekoot M, Lemkes HH. From gene to disease: Mutation in mitochondrial DNA and maternally inherited diabetes mellitus with deafness (MIDD). Ned. Tijdschr. Geneeskd. 2001;145:1153-1154.
35. Shih DQ, Stoffel M. Molecular etiologies of MODY and other early onset forms of diabetes. Curr. Diab. Rep. 2002;2:125-134.
36. Froguel P, Velho G. Genetic determinants of type 2 diabetes. Recent Prog. Horm. Res. 2001;56:91-105.
37. Brown GB, Xue-Qiao Z, Sacco DE, Alberts JJ. Lipid lowering and plaque regression. New insights into prevention of plaque disruption and clinical events in coronary disease. Circulation. 1993;87:1781-1791.
38. Rhoads GG, Gulbrandse CL, Kagan A. Serum lipoproteins and coronary artery disease in a population study of Hawaiian Japanese men. New. Engl. J. Med. 1976;294:293-298.
39. Yanni AE, Yatzidis HA, Kavantzas NG, Agapitos EV, Perrea DN, Karayannacos PE. Dietary L-aspartate and Lglutamate inhibit fatty streak initiation in cholesterol-fed rabbit. Nutr. Metab. Cardiovasc. Dis. 2003;13:80-86.
40. Segal P, Bachorik PS, Rifkind BM, Levy RI. Lipids and dyslipoproteinemia. In: Bernard JH, Nelson DA, Tomar RH, Washington JA, Saunders WB, eds. Clinical Diagnosis and Management by Laboratory Methods. 17th ed. Philadelphia: W.B. Saunders; 1984:180-203.
41. Bopanna KN, Kannan J, Sushma G, Balaraman R, Rathod SP. Antidiabetic and antihyperlipidemic effects of Neem seed kernel powder on alloxan diabetic rabbits. Indian J. Pharmacol. 1997;29:162-167.
42. Pushparaj P, Tan CH, Tan BK. Effects of Averrhoa bilimbi leaf extract on blood glucose and lipids in streptozotocindiabetic rats. J. Ethnopharmacol. 2000;72: 69-76.
43. Lehto S, Haffner SM, Pyorala K, Kallio V, Laakso M. Dyslipidemia and hyperglycemia predict coronary heart disease events in middle-aged patients with NIDDM. Diabetes. 1997;46:1354-1359.
44. Taskinen MR, Lahdenpera S, Syvanne M. New insights into lipid metabolism in non-insulin-dependent diabetes mellitus. Ann. Med. 1996;28:335-340.
45. Eisenberg S. Preferential enrichment of large sized very lowdensity lipoprotein populations with transferred cholesterylesters. J. Lipid Res. 1985;26:487-494.
46. Frayn KN. Insulin resistance and lipid metabolism. Curr. Opin. Lipidol. 1993;4:197-204.
47. Ashokumar N, Pari L, Manimakalai A, Selvarau. Effect of N-benzoyl-D-phenylalanine on streptozotocin induced changes in the lipid and lipoprotein profile in rats. J. Pharm. Pharmacol. 2005;57:359-366.
48. Blum J, Fridovich I. Inactivation of glutathione peroxidase by superoxide radical. Arch. Biochem. Biophys. 1985;240:500-508.